Research has shown that NLCs from the blood of CLL patients can activate the p44/42 MAPK signaling pathway within CLL cells through the SDF-1α/CXCR4 pathway, thereby protecting CLL B cells from apoptosis and promoting their survival in vitro (73). Here, CXCR4 is linked to B-cell chronic lymphocytic leukemia.